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Abstract
Introduction Genome-wide association studies of rheumatoid
arthritis (RA) have identified an association of the disease with a
6q23 region devoid of genes. TNFAIP3, an RA candidate gene,
flanks this region, and polymorphisms in both the TNFAIP3
gene and the intergenic region are associated with systemic
lupus erythematosus. We hypothesized that there is a similar
association with RA, including polymorphisms in TNFAIP3 and
the intergenic region.
Methods To test this hypothesis, we selected tag-single
nucleotide polymorphisms (SNPs) in both loci. They were
analyzed in 1,651 patients with RA and 1,619 control individuals
of Spanish ancestry.
Results Weak evidence of association was found both in the
6q23 intergenic region and in the TNFAIP3  locus. The
rs582757 SNP and a common haplotype in the TNFAIP3 locus
exhibited association with RA. In the intergenic region, two
SNPs were associated, namely rs609438 and rs13207033.
The latter was only associated in patients with anti-citrullinated
peptide antibodies. Overall, statistical association was best
explained by the interdependent contribution of SNPs from the
two loci TNFAIP3 and the 6q23 intergenic region.
Conclusions Our data are consistent with the hypothesis that
several RA genetic factors exist in the 6q23 region, including
polymorphisms in the TNFAIP3  gene, like that previously
described for systemic lupus erythematosus.
ACPA: anti-citrullinated peptide antibody; CI: confidence interval; GWA: genome-wide association; HWE: Hardy-Weinberg equilibrium; kb: kilo-
bases; LD: linkage disequilibrium; NF-B: nuclear factor-B; OR: odds ratio; PCR: polymerase chain reaction; RA: rheumatoid arthritis; RF: rheuma-
toid factor; SLE: systemic lupus erythematosus; SNP: single nucleotide polymorphism; TNFAIP3: tumor necrosis factor--induced protein 3; 
WTCCC: Wellcome Trust Consortium Case Controls.Arthritis Research & Therapy    Vol 11 No 2    Dieguez-Gonzalez et al.
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Introduction
The etiology of rheumatoid arthritis (RA) includes a genetic
component that has become amenable to investigation in
recent years. A major development has been the availability of
large-scale genome-wide association (GWA) studies. The first
GWA studies in RA were readily able to confirm the two clear-
est RA genetic factors – in the human leukocyte antigen region
and in the PTPN22 gene [1-3]. In addition, such studies have
found other significant associations. Some of these associa-
tions have already been confirmed in additional studies, such
as the TRAF1-C5 locus and the intergenic region in the 6q23
chromosome [2-5].
Two single nucleotide polymorphisms (SNPs) in 6q23, namely
rs6920220 and rs13207033 (or its perfect surrogate
rs10499194), have exhibited peak association with RA in an
independent manner [2]. This finding has been interpreted as
indicating the involvement of multiple genetic variants in RA
susceptibility [2]. The associated region does not contain any
known protein-coding sequence and lacks any evident func-
tional consequence [2,4], but a strong RA candidate gene, the
tumor necrosis factor--induced protein 3 (TNFAIP3) gene
(also known as A20), is at about 185 kilobases (kb; Figure 1
shows the positions of these two loci). In addition, the
rs6920220 SNP – together with SNPs in the TNFAIP3 gene
– have been found to be reproducibly associated with sys-
temic lupus erythematosus (SLE) susceptibility [6,7]. There-
fore, we have hypothesized that genetic variation in TNFAIP3
could also be involved in susceptibility to RA. This gene is an
excellent candidate for such an effect because it is a feedback
negative regulator of tumor necrosis factor signaling through
nuclear factor-B (NF-B) [8-10].
To test our hypothesis and to relate the TNFAIP3 locus to the
intergenic 6q23 region, we have genotyped tagSNPs at both
loci. Analysis in 1,651 RA patients and 1,619 control individu-
als revealed significant but weak associations at each locus.
Each of these signals was statistically reinforced when signals
in the other locus were accounted for. These results are con-
sistent with multiple RA genetic factors in chromosome 6q23
that include polymorphisms in the TNFAIP3 gene and that
interact with one another.
Materials and methods
DNA samples
Recruitment of samples included in this study has already
been described [11]. Samples were obtained from Caucasian
Spanish patients with RA (cases; n = 1,651) and control indi-
viduals (controls; n = 1,619). Cases and controls were
recruited in different hospitals, and an attempt was made to
match them by place of origin [see Table S1 in Additional data
file 1]. All patients were classified in accordance with the
1987 American College of Rheumatology criteria [12]. Partic-
ipants gave their informed consent and the ethical committees
of participating centers approved the study.
Single nucleotide polymorphism selection
Two separated regions of linkage disequilibrium (LD) in 6q23
were selected for analysis (Figure 1). The first, of 56 kb,
includes the TNFAIP3 gene and the region of high LD with
polymorphisms in the gene. The second, of 65 kb, is the LD
region that includes the two association peaks from previous
studies and that is limited by the recombination hot spots at
about 138.002 and 138.067 megabases described in the
HapMap CEU data (corresponding to samples with European
ancestry) [13]. These two regions were 144 kb apart. Tag-
SNPs [see Table S2 in Additional file 1] were selected from
the HapMap CEU data using the Haploview software [14] to
provide coverage with a pair-wise r2  0.8 of all of the SNPs
with minor allele frequency over 0.05 (TNFAIP3 locus) or 0.1
(intergenic locus). TagSNPs of the intergenic region included
the peak SNPs in previous studies [1] and rs13207033,
which is a perfect proxy of rs10499194 [2].
Single nucleotide polymorphism genotyping
PCRs were done with the Qiagen Multiplex PCR kit (Qiagen,
Valencia, CA, USA) on 30 ng genomic DNA. PCR products
were purified by Exo-SAP digestion with Exonuclease I (Epi-
centre, Madison, WI, USA) and Shrimp Alkaline Phosphatase
(GE Healthcare, Barcelona, Spain). Single-base extension
reactions were done using the SNaPshot Multiplex Kit
(Applied Biosystems, Foster City, CA, USA). Oligonucleotide
sequences are presented in the additional materials [see
Table S2 in Additional data file 1].
Figure 1
Map of the studied region in chromosome 6q23 Map of the studied region in chromosome 6q23. Recombination hot-spots from the HapMap CEU data are represented as black squares below the 
rule showing physical distances along the chromosome in kilobases. The positions of the two rheumatoid arthritis-associated peak single nucleotide 
polymorphisms from previous studies (rs13207033 and rs6920220) are marked by arrowheads. The position of the TNFAIP3 gene and its structure 
are shown.Available online http://arthritis-research.com/content/11/2/R42
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Statistical analysis
Hardy-Weinberg equilibrium (HWE) concordance was tested
in control samples. LD was analyzed using Haploview [14]. 2
tests for the 2 × 2 contingency tables were used to compare
allele frequencies. The minor allele of each SNP was taken as
reference for all comparisons, and minor allele frequencies are
reported in the tables. Allele frequencies of each SNP were
compared between controls from each center or region of ori-
gin, as a way to detect population heterogeneity. In addition,
combination of results after stratification by individuals' origin
was done following the Mantel-Haenszel approach, and heter-
ogeneity of effect sizes was explored using the Breslow-Day
test. ratio tests for the additive, dominant and recessive
genetic models were obtained relative to the co-dominant
model. Multivariate logistic regression analysis was used to
evaluate the conditional effect of the SNPs. For conditioning
on haplotype #5, a new genotype for this haplotype was cre-
ated with codes 0 (non-carrier), 1 (heterozygote), and 2
(homozygote) for each individual. No problem of colinearity
was detected with the inclusion in the model of haplotype #5
and SNP rs582757, which contributes to defining the haplo-
type, because the same allele of this SNP is present in three
other common haplotypes. Stepwise logistic regression with
all SNPs was conducted to detect the best multi-SNP models.
Haplotypes were estimated using the Phase 2.1 software
[15]. Odds ratios (ORs) for each haplotype were calculated
taking as reference all chromosomes not bearing the haplo-
type. A customized version of Statistica 7.0 (Statsoft, Tulsa,
OK, USA) was used for analyses except for statistical power,
which was estimated using the 'Power and sample size calcu-
lations' software [16].
Results
TNFAIP3 locus
Six tagSNPs were sufficient to cover the TNFAIP3 gene and
20 kb of flanking sequences to either side [see Table S2 and
Additional data file 1]. Genotypes of these tagSNPs were
obtained with a 99.1% call rate, and they were in HWE except
for the rs629953 SNP, which was excluded from further
analysis.
No significant differences in allele frequencies were found
between samples stratified by center of recruitment or region
of origin. Analysis of allele frequencies revealed that the minor
allele of the rs582757 SNP was significantly less frequent in
patients with RA than in control individuals (OR = 0.89; Table
1). Genotype frequency comparisons yielded similar results
(not shown). Estimation of the haplotype frequency distribu-
tion showed that only six haplotypes accounted for more than
98% of all chromosomes in patients with RA and controls
(Table 2). The rs582757 alleles were distributed in several
haplotypes and only the most common haplotype, which was
defined by the major alleles of the five tagSNPs, was signifi-
cantly different between patients with RA and control individ-
uals (haplotype #5 in Table 2). Multivariate analysis combining
haplotype #5 and rs582757 SNP genotypes revealed that any
of them could account for the association with RA and that the
two association signals were not independent (that is, associ-
ation with the haplotype genotypes was not significant when
conditioned on the rs582757 SNP, and vice versa) [see Table
S3 in Additional data file 1]. This finding suggests that associ-
ation is due to a causal polymorphism that is tagged by some
haplotypes containing the T allele of rs582757 (Table 2). No
significant change was detected by stratifying by sex (data not
shown) or by the presence of rheumatoid factor (RF) or anti-
citrullinated peptide antibodies (ACPAs) [see Table S4 in
Additional data file 1].
6q23 intergenic locus
We have included 10 tagSNPs in addition to the two SNPs
that have shown peak association in previous studies in the
6q23 intergenic locus [see Table S2 in Additional data file 1].
Genotypes of these 12 SNPs were in HWE and showed a
high call rate (99.0%) in our samples.
Comparison of allele frequencies did not reveal clear associa-
tion of any of these SNPs with RA (Table 3). Association in the
peak rs13207033 SNP was completely absent. The
rs6920220 SNP exhibited a trend (P = 0.07) in the same
direction that has previously been reported [1,2,4]. Only the
Table 1
Comparison of allele frequencies in the tag-SNPs covering 
variability in the TNFAIP3 gene
SNP MAF (% [n/N]) OR (95% CI) P
rs600144
Cases 25.9 (850/3278) 0.96 (0.9 to 1.1) NS
Controls 26.8 (857/3202)
rs11970361
Cases 5.7 (187/3300) 0.94 (0.8 to 1.2) NS
Controls 6.0 (194/3238)
rs11970411
Cases 10.2 (338/3300) 1.01 (0.9 to 1.2) NS
Controls 10.1 (328/3238)
rs582757
Cases 24.8 (816/3286) 0.89 (0.8 to 0.99) 0.041
Controls 27.0 (871/3220)
rs17780429
Cases 12.7 (418/3300) 0.91 (0.8 to 1.0) NS
Controls 13.8 (446/3236)
Shown is a comparison of the allele frequencies in the tag-single 
nucleotide polymorphisms (SNPs) covering variability in the 
TNFAIP3 gene between patients with rheumatoid arthritis (cases) 
and control individuals (controls). MAF, minor allele frequency; n, 
number of minor alleles; N, total number of alleles.Arthritis Research & Therapy    Vol 11 No 2    Dieguez-Gonzalez et al.
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rs609438 SNP had a P value that was just below 0.05, with
the minor allele exhibiting a lower frequency in patients with
RA than in control individuals (Table 3). The difference was
more marked when only women were considered (44.5% ver-
sus 48.9% in cases and controls, respectively; OR = 0.84,
95% confidence interval [CI] = 0.7 to 1.0; P = 0.006). Geno-
types of this SNP were best fitted by a dominant model, and
analysis according to this model revealed a clearer difference
between patients with RA and control individuals (frequencies
of CA + AA genotypes: 68.4% in cases versus 72.7% in con-
trols; OR = 0.81, 95% CI = 0.70 to 0.95; P = 0.008). The dif-
ference was greater in women (frequencies of CA + AA
genotypes in women: 66.8% in cases versus 74.0% in con-
trols; OR = 0.71, 95% CI = 0.58 to 0.86; P = 0.0006).
Genotype analyses of all of the other SNPs yielded findings
similar to those of the allele frequency comparisons, and no
differences were found by sex stratification in any of them (not
shown). Two of the SNPs in this locus exhibited significant
allele frequency differences between recruitment centers
(rs6920220, P = 0.01; and rs675520, P = 0.004), and one of
them was also different between regions of origin of the sam-
ples (rs6920220, P = 0.04). However, these differences did
not introduce detectable artefacts in the global results, as
shown by the similar results obtained above (Table 3) and with
the Mantel-Haenszel approach (OR = 1.12 versus ORM-H =
1.12 for rs6920220; and OR = 0.96 versus ORM-H = 0.97 for
rs675520) and lack of significant heterogeneity of the ORs as
assessed with the Breslow-Day test (rs6920220, P = 0.5; and
rs675520, P = 0.054).
Association of the rs6920220 SNP with RA has previously
been reported to be stronger in patients with ACPAs or RF
than in the ACPA-negative or RF-negative subgroup [4]. How-
ever, we did not detect any significant difference between
these patient subgroups [see Table S4 in Additional data file
1]. In contrast, we found that the rs13207033 SNP was asso-
ciated with RA only in the patients with ACPAs. Three other
SNPs also exhibited significant association exclusively in
ACPA-positive patients (Table 4). In all of these SNPs, the risk
allele was the most common. Conditional logistic regression of
these four SNPs, taken two by two, was unable to distinguish
between them (data not shown). No association was found
when the patient subgroups stratified by RF status were com-
pared with control individuals (data not shown).
Haplotype analysis of the 12 tagSNPs in this locus did not
reveal any significant association [see Table S5A in Additional
data file 1]. Also, no significant difference was detected in
haplotype frequencies between patients with ACPAs and con-
trol individuals [see Table S5B in Additional data file 1].
Statistical interaction between the 6q23 intergenic locus 
and TNFAIP3
We found weak evidence of association with RA both in
TNFAIP3 and in the 6q23 intergenic locus. SNPs from the two
loci were not in LD (all values of r2 < 0.07 in our samples).
However, lack of pair-wise correlation does not exclude com-
plex interdependence between the loci.
To explore more complex relationships, we used stepwise
logistic regression with the 17 SNPs. This unsupervised mul-
tivariate process was run both in a forward and in a backward
mode. That is, it was run starting with the most associated
SNP and adding a SNP in each step until the model was not
longer improved, or starting with a model incorporating all
SNPs and eliminating the least associated in each step until
the model deteriorated. The forward process yielded a best
model that combined the rs6920220 SNP from the intergenic
region and the rs582757 SNP from the TNFAIP3 locus (P =
0.009). The two SNPs were significantly associated when
considered conditional upon the other (P = 0.027 and P =
0.013, respectively). The backward stepwise procedure
yielded a best model with three SNPs (P = 0.009): two of the
intergenic region, namely rs13207033 and rs609438, and the
rs582757 SNP from the TNFAIP3 gene. Each made a signifi-
cant contribution to RA when assessed conditional upon the
other two (P  = 0.046, P  = 0.019, and P  = 0.007,
respectively).
Table 2
Distribution of estimated haplotype frequencies in the TNFAIP3 locus
Haplotype # rs600144 rs11970361 rs11970411 rs582757 rs17780429 Controls (n [%]) Cases (n [%]) OR (95% CI)
1T CGCA 427 (13.2%) 399 (12.1%) 0.92 (0.79 to 1.06)
2T TCT G 185 (5.7%) 175 (5.3%) 0.93 (0.76 to 1.16)
3T CGC G 443 (13.7%) 420 (12.7%) 0.93 (0.81 to 1.07)
4 C C G T G 849 (26.2%) 843 (25.5%) 0.98 (0.88 to 1.09)
5 T C G T G 1,159 (35.8%) 1,271 (38.5%) 1.14 (1.03 to 1.26)
6T CC T G 141 (4.4%) 162 (4.9%) 1.15 (0.91 to 1.44)
Distribution of estimated haplotype frequencies in the TNFAIP3 locus for control individuals (controls) and patients with rheumatoid arthritis 
(cases). The minor allele of each tag-single nucleotide polymorphism is presented in bold. Haplotypes with frequency over 2% are shown, ordered 
by the odds ratio (OR) comparing cases with controls. Haplotype #5 was significantly different. CI, confidence interval.Available online http://arthritis-research.com/content/11/2/R42
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Therefore, the two procedures showed that the best models
differentiating cases and controls include SNPs from the two
loci. In addition, they suggested interactions between them
because the P values of association for each SNP were lower
(more significant) in the multivariate analysis than when taken
individually. For example, the rs6920220 and the rs13207033
SNPs were not associated with RA in isolation (P = 0.07 and
P = 0.8, respectively), but they were associated in the multi-
variate models. If these results are confirmed, then they
amount to epistasis between the two loci.
Discussion
Association of RA susceptibility to SNPs in the intergenic
region of chromosome 6q23 has attracted strong interest in a
locus that, because of its lack of coding sequences, is espe-
cially difficult to investigate [1,2,4]. This was our motivation to
study the clearest candidate among the genes flanking this
locus, namely TNFAIP3. The recently reported coincident
association in SLE increased our interest and suggested that
the genetics of the region could be complex and include the
TNFAIP3 gene [6,7].
Our findings regarding the TNFAIP3  locus revealed weak
association with RA that could be explained either by the
rs582757 tagSNP or by the commonest haplotype. Because
of the weakness of the association and the multiple SNPs
tested, these findings should be considered tentative. How-
ever, confidence in this association is increased by consider-
ing the summary statistics from the Wellcome Trust
Consortium Case Controls (WTCCC) GWA study [1], which
included 1,860 patients with RA and 2,938 healthy control
individuals. That study yielded very similar results at the
rs582757 SNP (25.0% versus 27.1% in RA patients and con-
trol individuals, respectively; OR = 0.90; P = 0.02). Additional
preliminary data from a larger study are also concordant with
association with RA of SNPs in the TNFAIP3 gene [17]. It is
also of interest that a TNFAIP3 SNP with strong correlation (r2
> 0.9) with the rs582757 SNP is associated with reduced
expression of TNFAIP3 and with coronary artery disease in
patients with type 2 diabetes [18].
Regarding the 6q23 intergenic region, we found weak associ-
ation with a previously unreported SNP, rs609438, and repli-
cation of association with the rs13207033 SNP. This latter
was observed only in patients positive for ACPAs. Previous
reports could be interpreted as supporting this preferential
association of the rs13207033 SNP, because association
with this SNP was much clearer in the study conducted by
Plenge and coworkers [2] (P = 4 × 10-7), in which all patients
were ACPA positive than in the WTCCC GWA study [1] (P =
0.01), in which the patients were unselected. There are
already antecedents of this type of preferential association in
relation to the ACPA status of patients with RA, including the
shared epitope, the PTPN22 nonsynonymous SNP and IRF5
[19-21]. However, specific analysis in other sample collec-
Table 3
Allele frequencies of the 12 tagSNPs from the intergenic 6q23 
region: cases versus controls
SNP MAF% (n/N) OR (95% CI) P
rs566097
Cases 11.4 (364/3,198) 0.99 (0.8 to 1.1) NS
Controls 11.5 (367/3,182)
rs13207033
Cases 29.3 (897/3,062) 0.98 (0.9 to 1.1) NS
Controls 29.7 (914/3,082)
rs489738
Cases 17.7 (559/3,164) 0.94 (0.8 to 1.1) NS
Controls 18.6 (586/3,158)
rs12194935
Cases 23.0 (726/3,160) 1.00 (0.9 to 1.1) NS
Controls 23.0 (726/3,154)
rs536331
Cases 42.1 (1,345/3,194) 0.99 (0.9 to 1.1) NS
Controls 42.5 (1,351/3,182)
rs675520
Cases 48.6 (1,507/3,104) 0.96 (0.9 to 1.1) NS
Controls 49.5 (1,520/3,070)
rs6920220
Cases 22.0 (703/3,200) 1.12 (1.0 to 1.3) 0.07
Controls 20.1 (639/3,178)
rs694069
Cases 39.0 (1,244/3,188) 0.96 (0.9 to 1.1) NS
Controls 40.0 (1,273/3,180)
rs6917441
Cases 24.9 (790/3,178) 0.95 (0.9 to 1.1) NS
Controls 25.8 (816/3,164)
rs647108
Cases 39.7 (1,265/3,188) 0.95 (0.9 to 1.0) NS
Controls 40.9 (1,301/3,178)
rs9321627
Cases 22.7 (728/3,202) 0.96 (0.9 to 1.1) NS
Controls 23.5 (749/3,186)
rs609438
Cases 45.1 (1,436/3,182) 0.91 (0.8 to 1.0) 0.047
Controls 47.6 (1,513/3,178)
Shown are the allele frequencies of the 12 tag-single nucleotide 
polymorphisms (SNPs) from the intergenic 6q23 region in patients 
with rheumatoid arthritis (cases) and control individuals (controls). 
MAF, minor allele frequency; n, number of minor alleles; N, total 
number of alleles.Arthritis Research & Therapy    Vol 11 No 2    Dieguez-Gonzalez et al.
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tions will be required to confirm this specificity of the
rs13207033 association.
An unexpected result was the lack of association with RA of
the rs6920220 SNP Association of this SNP with RA has pre-
viously been demonstrated in several studies with an overall
OR of 1.23 [1,2,4]. Our study had enough power to detect this
effect (power = 0.8 for P  = 0.01). However, we found a
weaker effect (OR = 1.12) than in previous studies. Such a dif-
ference in effect size between studies is common, and recent
examples have been found in confirmed RA genetic factors
such as STAT4 and TRAF1-C5 [5]. In these examples, and in
many others, the observed effect sizes were weaker in replica-
tion studies than in the discovery study. This phenomenon has
been characterized as the 'winner's curse'. It means that find-
ings of discovery studies often overestimate the true associa-
Table 4
Allele frequency differences in tagSNPs of the intergenic 6q23 region: ACPA-positive cases versus controls
SNP MAF% (n/N) OR (95%CI) P
rs566097
ACPA+ cases 10.9 (84/772) 0.94 (0.7 to 1.2) NS
Controls 11.5 (367/3,190)
rs13207033
ACPA+ cases 25.1 (185/736) 0.80 (0.66 to 0.96) 0.015
Controls 29.7 (914/3,082)
rs489738
ACPA+ cases 18.2 (138/760) 0.97 (0.8 to 1.2) NS
Controls 18.6 (586/3,158)
rs12194935
ACPA+ cases 26.1 (198/758) 1.18 (1.0 to 1.4) NS
Controls 23.0 (726/3,154)
rs536331
ACPA+ cases 37.9 (292/770) 0.83 (0.71 to 0.97) 0.023
Controls 42.4 (1,351/3,184)
rs675520
ACPA+ cases 44.5 (334/750) 0.82 (0.70 to 0.96) 0.014
Controls 49.5 (1,520/3,070)
rs6920220
ACPA+ cases 22.3 (172/770) 1.15 (0.95 to 1.39) NS
Controls 20.1 (639/3,184)
rs694069
ACPA+ cases 35.5 (273/770) 0.82 (0.70 to 0.97) 0.019
Controls 40.1 (1,276/3,186)
rs6917441
ACPA+ cases 27.9 (212/760) 1.11 (0.9 to 1.3) NS
Controls 25.8 (816/3,166)
rs647108
ACPA+ cases 41.9 (321/766) 1.04 (0.9 to 1.2) NS
Controls 41.0 (1,306/3,184)
Allele frequency differences in tag-single nucleotide polymorphism (SNP) of the intergenic 6q23 region between patients with rheumatoid arthritis 
positive for anti-citrullinated peptide antibodies (ACPA+ cases) and control individuals (controls). MAF, minor allele frequency; n, number of minor 
alleles; N, total number of alleles.Available online http://arthritis-research.com/content/11/2/R42
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tion because they are conditional on those studies being the
first to detect the association [22]. An alternative explanation
for the lack of association in our study could be related to the
differences in rs6920220 allele frequencies that were
observed between recruitment centers. However, we consider
this to be unlikely because the global comparison between
patients with RA and control individuals showed that they
were identical when the samples were taken as a whole or
when they were stratified by place of origin.
The two large and comprehensive SLE studies of the 6q23
region have yielded multiple independent association signals,
including polymorphisms in the TNFAIP3 gene [6,7]. At least
three independent signals were detected in each of the two
studies, although they were not completely concordant
between each other or with the peak associations previously
reported in RA. Our multivariate logistic analyses produced
similar results, suggesting that polymorphisms in the two loci
contribute to RA susceptibility. It therefore seems possible
that this region contains multiple genetic factors shared by RA
and SLE. Our data do not allow us to be more conclusive.
TNFAIP3 is a clear candidate for a role in RA by virtue of the
anti-inflammatory effects of its encoded protein. It is involved
in many regulatory feedback loops through the cooperative
activity of its two ubiquitin-editing domains [9]. TNFAIP3 pro-
tein levels are drastically increased upon NF-B stimulation by
various factors, including tumor necrosis factor and inter-
leukin-1 [9,10]. Once upregulated, TNFAIP3 inhibits NF-B
activity at multiple levels. Therefore, it seems likely that poly-
morphisms that reduce expression or function of TNFAIP3 will
favor exaggerated inflammatory responses that may contribute
to RA development and expression. However, our study has
only provided suggestive evidence of the involvement of this
gene in RA susceptibility. This evidence is reinforced by data
from the WTCCC GWA study [1] and preliminary data pre-
sented at the 2008 American College of Rheumatology meet-
ing [17]. Investigation of the 6q23 region should proceed with
increased enthusiasm, given its likely involvement in multiple
immune-mediated diseases and the possible involvement of
TNFAIP3 – an important regulator of the NF-B pathway.
Conclusions
We have found evidence of multiple RA genetic factors in the
6q23 region including polymorphisms in the TNFAIP3 gene.
These factors appear to be shared with SLE susceptibility.
Involvement of TNFAIP3 is of practical interest, given its inhib-
itory effect on the NF-B pathway. Nevertheless, there remain
many aspects that require further analysis: confirmation of our
results, delineation of genetic influences on specific RA sub-
phenotypes, and identification of the functional variants in this
locus and their effects.
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